DnB Asset Management AS raised its stake in DaVita Inc. (NYSE:DVA – Get Rating) by 2.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,513 shares of the company’s stock after acquiring an additional 300 shares during the quarter. DnB Asset Management AS’s holdings in DaVita were worth $1,080,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the business. NuWave Investment Management LLC acquired a new position in DaVita in the second quarter valued at $173,000. Teachers Retirement System of The State of Kentucky increased its stake in DaVita by 8.1% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 392,458 shares of the company’s stock valued at $44,391,000 after purchasing an additional 29,494 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in DaVita by 14.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,815 shares of the company’s stock valued at $1,450,000 after purchasing an additional 1,577 shares during the last quarter. Toroso Investments LLC increased its stake in DaVita by 13.6% in the first quarter. Toroso Investments LLC now owns 6,394 shares of the company’s stock valued at $723,000 after purchasing an additional 766 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC increased its stake in DaVita by 585.7% in the first quarter. Worldquant Millennium Advisors LLC now owns 62,878 shares of the company’s stock valued at $7,112,000 after purchasing an additional 53,708 shares during the last quarter. 88.47% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft dropped their target price on DaVita from $150.00 to $97.00 and set a “buy” rating for the company in a research note on Tuesday, August 2nd. Truist Financial lowered their price target on DaVita from $110.00 to $90.00 and set a “hold” rating for the company in a research report on Wednesday, June 22nd. Cowen lowered their price target on DaVita to $95.00 in a research report on Tuesday, August 9th. Bank of America lowered their price target on DaVita from $110.00 to $90.00 and set an “underperform” rating for the company in a research report on Tuesday, June 21st. Finally, UBS Group boosted their price target on DaVita from $106.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, August 19th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $100.43.
DaVita Price Performance
DaVita (NYSE:DVA – Get Rating) last issued its earnings results on Monday, August 1st. The company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.21. DaVita had a return on equity of 84.69% and a net margin of 7.17%. The company had revenue of $2.93 billion during the quarter, compared to the consensus estimate of $2.93 billion. During the same quarter in the prior year, the business earned $2.64 earnings per share. The company’s revenue was up .4% compared to the same quarter last year. On average, equities analysts anticipate that DaVita Inc. will post 7.64 EPS for the current fiscal year.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.